Drug maker Lupin on Wednesday said it has launched a combination drug for patients with heart failure (HF) conditions.
The company said it has introduced Sacubitril and Valsartan under two brand names, Valentas and Arnipin, in strengths of 200 mg, 100 mg, and 50 mg, in India.
In India, HF remains one of the most prevalent causes of death in patients suffering from chronic heart failure and the estimated prevalence ranges from 1.3 to 4.6 million, the drug maker said in a statement.
Valentas and Arnipin are indicated to reduce repeated hospitalisation and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure.
"The launch of Valentas and Arnipin aligns with this commitment and offers patients an important treatment option and fulfils an unmet need, while reducing the cost of therapy," Lupin President - India Region Formulations Rajeev Sibal stated.
Glenmark Pharmaceuticals launches drug to treat heart failure in India
World Heart Day: Doctors say lifestyle, dietary change must for good health
Research identifies new prognostic biomarker for heart failure patients
Lupin posts net profit of Rs 130 cr in Q2, revenue rises to Rs 4,145 cr
Glenmark pharma launches generic version of Novartis' heart failure drug
Leyland bags contract to supply 500 buses to Sri Lanka Transport Board
India IT spending to reach $110.3 bn in 2023 amid global slowdown: Report
Udaan product shipment jumps six-fold to 1.7 bn in 2022
Rs 20,000 cr FPO: Adani Enterprises to invest Rs 11,000 cr in green capex
Jubilant FoodWorks brings American chicken brand Popeyes to Chennai
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)